Nicholas Robert

Summary

Affiliation: US Oncology
Country: USA

Publications

  1. ncbi request reprint Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer
    Nicholas Robert
    US Oncology Research Inc, Houston, TX, USA
    J Clin Oncol 24:2786-92. 2006
  2. doi request reprint Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial
    Nicholas J Robert
    Virginia Cancer Specialists, US Oncology, Fairfax, VA, USA
    Clin Breast Cancer 11:82-92. 2011
  3. doi request reprint RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer
    Nicholas J Robert
    Virginia Cancer Specialists, US Oncology, Fairfax, VA, USA
    J Clin Oncol 29:1252-60. 2011
  4. doi request reprint Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer
    Nicholas J Robert
    US Oncology Research, Inc, The Woodlands, TX, USA
    Breast Cancer Res Treat 126:101-8. 2011
  5. doi request reprint Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study
    Nicholas Robert
    US OncologyVirginia Cancer Specialists, 8503 Arlington Blvd, 400, Fairfax, VA, USA
    Breast Cancer Res Treat 125:115-20. 2011
  6. ncbi request reprint HER2-positive advanced breast cancer
    Nicholas J Robert
    US Oncology Research Network, Fairfax Northern Virginia Hematology Oncology, 8503 Arlington Boulevard, 400, Fairfax, VA 22031, USA
    Hematol Oncol Clin North Am 21:293-302. 2007
  7. doi request reprint Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer
    David Loesch
    US Oncology Research, The Woodlands, TX, USA
    J Clin Oncol 28:2958-65. 2010
  8. ncbi request reprint Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer
    David Loesch
    U S Oncology, Inc, Houston, TX, USA
    J Clin Oncol 20:3857-64. 2002
  9. ncbi request reprint A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer
    David M Loesch
    Oncology and Hematology Associates, Inc, Indianapolis, IN 46227 0900, USA
    Breast Cancer Res Treat 77:115-23. 2003
  10. doi request reprint Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes
    Joanne L Blum
    Baylor Charles A Sammons Cancer Center, Dallas, Texas, USA
    Clin Breast Cancer 7:850-6. 2007

Detail Information

Publications23

  1. ncbi request reprint Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer
    Nicholas Robert
    US Oncology Research Inc, Houston, TX, USA
    J Clin Oncol 24:2786-92. 2006
    ..This randomized, multicenter, phase III trial evaluated the efficacy and safety of trastuzumab and paclitaxel with or without carboplatin as first-line therapy for women with HER-2-overexpressing metastatic breast cancer (MBC)...
  2. doi request reprint Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial
    Nicholas J Robert
    Virginia Cancer Specialists, US Oncology, Fairfax, VA, USA
    Clin Breast Cancer 11:82-92. 2011
    ....
  3. doi request reprint RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer
    Nicholas J Robert
    Virginia Cancer Specialists, US Oncology, Fairfax, VA, USA
    J Clin Oncol 29:1252-60. 2011
    ....
  4. doi request reprint Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer
    Nicholas J Robert
    US Oncology Research, Inc, The Woodlands, TX, USA
    Breast Cancer Res Treat 126:101-8. 2011
    ..Grade 1/2 alopecia was seen in 8% of patients. This phase II study of dose-dense, single-agent pemetrexed showed moderate activity in the first-line setting with acceptable toxicity and no significant alopecia...
  5. doi request reprint Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study
    Nicholas Robert
    US OncologyVirginia Cancer Specialists, 8503 Arlington Blvd, 400, Fairfax, VA, USA
    Breast Cancer Res Treat 125:115-20. 2011
    ..Administering adjuvant dose-dense AC followed by 260 mg/m(2) dose-dense nab-paclitaxel was feasible in women with early-stage BC, with manageable AEs. Most patients had ≤ 1 grade neuropathy 2 months after treatment completion...
  6. ncbi request reprint HER2-positive advanced breast cancer
    Nicholas J Robert
    US Oncology Research Network, Fairfax Northern Virginia Hematology Oncology, 8503 Arlington Boulevard, 400, Fairfax, VA 22031, USA
    Hematol Oncol Clin North Am 21:293-302. 2007
    ..This article reviews the biology of HER2, testing for HER2, clinical studies evaluating HER2-based therapies, side effects (specifically cardiotoxicity), and strategies for HER2-based therapies...
  7. doi request reprint Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer
    David Loesch
    US Oncology Research, The Woodlands, TX, USA
    J Clin Oncol 28:2958-65. 2010
    ..This study compared disease-free survival (DFS) obtained with two different regimens of adjuvant therapy in high-risk breast cancer...
  8. ncbi request reprint Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer
    David Loesch
    U S Oncology, Inc, Houston, TX, USA
    J Clin Oncol 20:3857-64. 2002
    ..To determine the activity of weekly paclitaxel plus carboplatin as first-line therapy in patients with advanced breast cancer (ABC) by assessing response rate, survival, and safety...
  9. ncbi request reprint A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer
    David M Loesch
    Oncology and Hematology Associates, Inc, Indianapolis, IN 46227 0900, USA
    Breast Cancer Res Treat 77:115-23. 2003
    ..This phase II multicenter trial evaluated the efficacy and toxicity of weekly paclitaxel, 5-fluorouracil, and leucovorin administered as first-line therapy for metastatic breast cancer...
  10. doi request reprint Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes
    Joanne L Blum
    Baylor Charles A Sammons Cancer Center, Dallas, Texas, USA
    Clin Breast Cancer 7:850-6. 2007
    ..We examined albumin-bound paclitaxel (100 mg/m2 or 125 mg/m2 administered weekly) to determine the antitumor activity in patients with MBC whose disease progressed despite conventional taxane therapy...
  11. ncbi request reprint The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer
    Nicholas J Robert
    The Cancer Center, Inova Fairfax Hospital, Falls Church, VA, USA
    Semin Oncol 31:106-46. 2004
    ..The toxicity profile of NPLD is similar to that of conventional doxorubicin, but toxicities are less severe and NPLD is better tolerated than conventional doxorubicin at higher doses...
  12. ncbi request reprint Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer
    Martin S Tallman
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago 60611, USA
    N Engl J Med 349:17-26. 2003
    ..High-dose chemotherapy with autologous hematopoietic stem-cell transplantation has been reported to be effective in the adjuvant setting for patients at high risk for relapse...
  13. ncbi request reprint A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
    Paul E Goss
    Division of Hematology Oncology, Princess Margaret Hospital, Toronto, ON, Canada
    N Engl J Med 349:1793-802. 2003
    ..The aromatase inhibitor letrozole, by suppressing estrogen production, might improve the outcome after the discontinuation of tamoxifen therapy...
  14. doi request reprint Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen
    Paul E Goss
    Massachusetts General Hospital Cancer Center, 55 Fruit St, Lawrence House, LRH 302, Boston, MA 02114, USA
    J Clin Oncol 26:1948-55. 2008
    ..When the trial was unblinded, patients who received placebo (PLAC) were offered LET...
  15. pmc Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by
    Minetta C Liu
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road NW, Washington, DC 20007 2198, USA
    Cancer Treat Rev 34:223-30. 2008
    ..A secondary aim was to assess if a higher dose (10 mcg/kg/day) of G-CSF is more efficacious than the conventional dose (5 mcg/kg/day) in this setting...
  16. ncbi request reprint Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Breast Cancer Res Treat 99:295-300. 2006
    ..Analyses were conducted to examine the relationships between duration of treatment on MA.17 and outcomes...
  17. ncbi request reprint Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17
    Paul E Goss
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA
    J Natl Cancer Inst 97:1262-71. 2005
    ..This report presents updated findings from the trial...
  18. ncbi request reprint Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study
    Lorie L Hughes
    Department of Radiation Oncology, WellStar Kennestone Hospital, Marietta, GA 30060, USA
    Cancer 101:969-72. 2004
    ..In the current study, we report the efficacy of pelvic RT with this dose-fractionation scheme in the induction of ovarian ablation...
  19. doi request reprint Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17
    Hyman B Muss
    University of Vermont College of Medicine, 1 South Prospect St, Saint Joseph 3400, Burlington, VT 05401, USA
    J Clin Oncol 26:1956-64. 2008
    ..Breast cancer incidence increases with age and more than 1,300 women age 70 years or older were enrolled onto MA.17, making it ideal to explore the benefits, toxicities, and quality of life (QOL) impact of letrozole on older women...
  20. ncbi request reprint Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17
    Paul E Goss
    Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 25:2006-11. 2007
    ..MA.17 randomized postmenopausal women after 5 years of tamoxifen, to letrozole or placebo. We present outcomes according to tumor receptor status...
  21. pmc Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer
    Henning T Mouridsen
    Department of Oncology, Rigshospitalet, Copenhagen, Denmark
    MedGenMed 7:20. 2005
    ..Other trials continue to investigate some of these adjuvant treatment strategies...
  22. ncbi request reprint Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women
    Timothy J Whelan
    McMaster University, Hamilton, Canada
    J Clin Oncol 23:6931-40. 2005
    ..To evaluate the impact of letrozole compared with placebo after adjuvant tamoxifen on quality of life (QOL) in the MA.17 trial...
  23. ncbi request reprint The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women
    Henning T Mouridsen
    Department of Oncology, Rigshospitalet, 9 Blegdamsvej, Copenhagen DK 2100, Denmark
    Eur J Cancer 41:1678-89. 2005
    ..A number of trials further evaluating the three adjuvant treatment strategies are ongoing...